Zenith Epigenetics Corp.

Seal Rock Therapeutics, Inc.

Samuel David Brown

Olesya Kharenko

Shuang Liu

Craig Alan Coburn

Peter Guzzo

Peter Ronald Young

Bryan Cordell Duffy

Described herein are compounds, including pharmaceutically acceptable salts and solvates thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.

ASK1 inhibitor compounds and uses thereof

The present application relates to substituted heterocycles compound of Formula I and pharmaceutical compositions thereof useful for the inhibition of BET protein function by binding to bromodomains (Formula I). 

Substituted heterocycles as bromodomain inhibitors

The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.

Inhibitors of bromodomains

Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.

Growing community of inventors

San Carlos, CA, United States of America

Samuel David Brown